UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (Right to Buy) | Â (1) | 12/14/2024 | Common Stock | 291,499 (3) | $ 0.96 (3) | D | Â |
Stock Option (Right to Buy) | Â (2) | 12/14/2026 | Common Stock | 48,916 (3) | $ 1 (3) | D | Â |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Heft Robert C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM, MA 02451 |
 X |  |  |  |
/s/ Gregory Weaver, Attorney in Fact | 12/29/2017 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The option vested over a three-year period commencing on January 24, 2014 in twelve equal quarterly installments and became fully vested and exercisable as of January 24, 2017. |
(2) | The option vests over a three-year period commencing on January 24, 2016 in twelve equal quarterly installments. |
(3) | Exercise price and number of option shares, as applicable, have been adjusted to reflect the Issuer's 1-for-20 reverse stock split of its issued and outstanding shares of common stock effected on December 19, 2017. |
 Remarks: Exhibit 24 - Power of Attorney. Gregory Weaver, Chief Financial Officer, is signing on behalf of Dr. Robert Heft pursuant to a Power of Attorney dated December 16, 2017, which is attached hereto as an exhibit. |